Los Angeles Capital Management
RLMD icon

Los Angeles Capital Management’s Relmada Therapeutics RLMD Stock Holding History

Los Angeles Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Buy
+155,713
New +$1.09M ﹤0.01% 728
2023
Q3 		– Sell
-11,877
Closed -$29.2K – 1218
2023
Q2 		$29.2K Buy
11,877
+127
+1% +$351 ﹤0.01% 1146
2023
Q1 		$26.6K Sell
11,750
-901
-7% -$3.11K ﹤0.01% 1150
2022
Q4 		$44.2K Buy
12,651
+6,600
+109% +$58K ﹤0.01% 1179
2022
Q3 		$224K Buy
+6,051
New +$168K ﹤0.01% 1154

Other funds holding RLMD

Jupiter Topco
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Los Angeles Capital Management's RLMD Position: Q2 2026 in Review

Los Angeles Capital Management opened a new position in Relmada Therapeutics (RLMD) in Q2 2026: 155,713 shares worth $1.08M. The stake represents ﹤0.01% of the portfolio and ranks #728 among its holdings. This is a return to the name: Los Angeles Capital Management previously reported a position in RLMD as recently as Q2 2023.

Los Angeles Capital Management first reported a position in RLMD in Q3 2022 and has held it in 5 quarters since. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Los Angeles Capital Management held 155,713 shares of Relmada Therapeutics worth $1.08M as of Q2 2026.
  • Relmada Therapeutics was a new Los Angeles Capital Management position in Q2 2026.
  • Relmada Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #728 holding.
  • Los Angeles Capital Management first reported a position in Relmada Therapeutics in Q3 2022 and has held it in 5 quarters since.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.